| Title | Author(s) | Issue date | ???itemlist.??? |
| Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients | Makis, A. C.; Hatzimichael, E. C.; Mavridis, A.; Bourantas, K. L. | 24-Nov-2015 | - |
| C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease | Makis, A. C.; Hatzimichael, E. C.; Stebbing, J.; Bourantas, K. L. | 24-Nov-2015 | - |
| Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment | Makis, A. C.; Hatzimichael, E. C.; Kolios, G.; Bourantas, K. L. | 24-Nov-2015 | - |
| The genomics of new drugs in sickle cell disease | Makis, A. C.; Hatzimichael, E. C.; Stebbing, J. | 24-Nov-2015 | - |
| Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes | Voulgari, P. V.; Hatzimichael, E. C.; Tsiara, S.; Tzallas, C.; Drosos, A. A.; Bourantas, K. L. | 24-Nov-2015 | - |
| A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival | Christou, L.; Hatzimichael, E. C.; Sotsiou-Candila, F.; Siamopoulos, K.; Bourantas, K. L. | 24-Nov-2015 | - |
| Peri-operative use of recombinant human erythropoietin in Jehovah's Witnesses | Bourantas, K. L.; Xenakis, T. A.; Hatzimichael, E. C.; Kontogeorgakos, V.; Beris, A. E. | 24-Nov-2015 | - |
| Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients | Bourantas, K. L.; Hatzimichael, E. C.; Makis, A. C.; Kapsali, E.; Tsiara, S.; Christou, L.; Seferiadis, K. | 24-Nov-2015 | - |
| Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient | Makis, A. C.; Chaliasos, N.; Hatzimichael, E. C.; Bourantas, K. L. | 24-Nov-2015 | - |
| The role of cytokines in sickle cell disease | Makis, A. C.; Hatzimichael, E. C.; Bourantas, K. L. | 24-Nov-2015 | - |
| Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders | Bourantas, K. L.; Hatzimichael, E. C.; Makis, A. C.; Chaidos, A.; Kapsali, E. D.; Tsiara, S.; Mavridis, A. | 24-Nov-2015 | - |
| Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients | Sfagos, C.; Makis, A. C.; Chaidos, A.; Hatzimichael, E. C.; Dalamaga, A.; Kosma, K.; Bourantas, K. L. | 24-Nov-2015 | - |
| Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases | Panteli, K. E.; Hatzimichael, E. C.; Bouranta, P.; Katsaraki, A.; Seferiadis, K.; Stebbing, J.; Bourantas, K. L. | 24-Nov-2015 | - |
| Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia | Hatzimichael, E. C.; Christou, L.; Bai, M.; Kolios, G.; Kefala, L.; Bourantas, K. L. | 24-Nov-2015 | - |
| Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis | Makis, A. C.; Galanakis, E.; Hatzimichael, E. C.; Papadopoulou, Z. L.; Siamopoulou, A.; Bourantas, K. L. | 24-Nov-2015 | - |
